查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2094833

豬疫苗市場－2026-2032年全球市場預測

Swine Vaccines Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，豬隻疫苗市場規模將成長至 30.1 億美元，複合年成長率為 6.30%。

主要市場統計數據
基準年 2025 19.6億美元
預計年份：2026年 20.8億美元
預測年份 2032 30.1億美元
複合年成長率 (%) 6.30%

豬疫苗在現代養豬生產中發揮核心作用，它保障動物健康、食品安全、合理使用抗菌藥物，並維持國際畜牧貿易的持續進行。該領域面臨持續的疾病壓力，這些疾病來自一些具有重要經濟意義的病原體，例如豬繁殖與呼吸綜合症病毒、豬環狀病毒2型、豬肺炎黴漿菌、豬流感病毒、經典豬瘟病毒和非洲豬瘟病毒。雖然有些疾病可以透過現有的免疫接種計畫進行常規控制，但對於其他疾病，仍需進行緊急研究，以開發更安全、更有效、更容易規模化的疫苗技術。

豬疫苗接種的需求日益與豬群層面的疾病預防而非被動的疾病控制掛鉤。生產者、獸醫、綜合畜牧經營者和公共衛生機構都在優先考慮那些能夠降低死亡率、提高繁殖性能、減輕臨床症狀並控制繼發性細菌感染疾病（從而減少抗生素使用）的疫苗接種方案。監管、生物安全標準、疾病監測以及消費者對負責任生產的豬肉的期望，都進一步強化了疫苗接種作為豬隻健康管理核心支柱的作用。

豬疫苗領域涵蓋減毒活病毒疫苗、去活化疫苗、次單位疫苗、重組疫苗、載體疫苗和自有品牌疫苗，其創新重點在於擴大保護範圍、開發與DIVA系統兼容的診斷方法、改進佐劑、實現無針注射、提高熱穩定性以及快速進行毒株匹配。隨著養豬系統日益集中化和全球互聯，疫苗策略正朝著以診斷、農場數據和區域流行病學為基礎的綜合疾病預防方向發展。

豬隻疫苗現狀的變革性變化

受疾病複雜性增加、生產模式演變以及與動物健康和公共衛生目標日益緊密結合等因素的影響，豬隻疫苗領域正經歷著變革性的變化。非洲豬瘟（AFS）凸顯了生豬供應鏈在跨國疾病面前的脆弱性，即使在獸醫基礎設施完善的地區也是如此。迄今為止，由於缺乏廣泛上市、全球部署的非洲豬瘟疫苗，預防措施主要依賴生物安全、監測、流動限制和撲殺政策。同時，減毒活病毒疫苗、基因敲除疫苗、載體疫苗和次單位疫苗的研發正在加速推進。

人工智慧對豬疫苗的累積影響

人工智慧（AI）正在變革豬疫苗研發、疾病監測和豬群健康管理方面的決策。在疫苗研究中，AI驅動的生物資訊學有助於識別保守抗原、評估免疫相關蛋白的結構、比較病毒和細菌基因組，並確定實驗室檢驗的候選疫苗的優先順序。這對於遺傳多樣性和病毒株多樣性高的病原體尤其重要，因為持續保護難以實現，例如豬隻繁殖與呼吸綜合症病毒（PRRSV）和豬流感。

關於豬疫苗的關鍵區域見解

亞太地區是豬隻疫苗策略上最重要的地區之一，因為該地區涵蓋了全球眾多最大的豬肉生產國和消費國。中國不僅擁有龐大的生豬存欄量，而且由於非洲豬瘟疫情對生產系統、生物安全投資和疫苗研發重點的持續影響，中國在亞太地區的疾病動態中仍扮演著核心角色。東南亞國家持續面臨地方性疾病和新興疾病的壓力，包括經典豬瘟、豬繁殖與呼吸綜合症（PRRS）、豬圓環病毒2型（PCV2）相關疾病以及非洲豬瘟的入侵，因此，疫苗接種計劃與監測活動、對小規模農戶的支持以及養豬場的現代化密切相關。日本、韓國和澳洲擁有先進的獸醫監管體系和高標準的生物安全體系，尤其是澳大利亞，由於對幾種主要豬病原體的感染率較低，因此堅持「預防優先」的策略。

關於豬疫苗的關鍵小組見解

雖然北約成員國並非獸藥市場壟斷集團，但許多成員國與北美和歐洲的主要豬隻生產國重疊。在這些國家，動物健康安全與國家韌性、糧食系統連續性、生物安全以及防止農業供應鏈遭受意外或人為破壞密切相關。因此，豬疫苗的準備工作是更廣泛的「同一健康」和農業安全框架的一部分，對於應對非洲豬瘟和古典豬瘟等跨境疾病尤其重要。

主要國家豬疫苗使用趨勢

由於中國生豬養殖業規模龐大，且在非洲豬瘟疫情爆發後實施了徹底的結構性改革，因此中國仍然是豬疫苗最重要的供應國之一。儘管大型養殖場正在擴大生物安全和獸醫規程，但疾病管制的重點仍是防範非洲豬瘟、豬繁殖與呼吸症候群（PRRS）、豬圓環病毒2型（PCV2）、經典豬瘟和其他地方性病原體。美國擁有龐大且高度整合的生豬產業，疫苗接種計畫在控制PRRS、PCV2、黴漿菌、豬流感、紅斑病和其他生產相關疾病方面發揮核心作用。完善的診斷網路、獸醫主導的健康管理計劃和生物安全程序指導疫苗的選擇和接種時間。在日本，生物安全標準高，獸醫系統完善，疫苗接種決策基於疫情情勢、監管控制及食品安全預期。雖然印度的養豬業與該國的整體畜牧業相比規模較小，但它在某些地區發揮著至關重要的作用，尤其是在東北地區，疫苗接種、獸醫服務和疾病意識對於維持小規模農戶的韌性至關重要。

為豬疫苗產業領導者提供的實用建議

行業領導者應優先考慮將疫苗接種、診斷、生物安全、營養、福利和農場管理相結合的綜合性豬隻健康計劃，而不是僅依賴疫苗作為單一解決方案。疫苗接種方案的製定應基於農場的具體疾病史、檢查室確診結果、必要的病原體測序分析、生產階段的風險、母源抗體狀況以及在獸醫監督下的療效監測。

豬疫苗分析的調查方法

本執行摘要採用系統化的二手資料研究途徑編寫，重點關注檢驗的動物健康、獸醫流行病學和監管資訊。主要資訊來源包括國家獸醫主管機關、政府間動物衛生機構的公開資料、同儕審查的科學文獻、疾病報告系統、動物衛生指南和經認可的獸醫公共衛生資訊來源。

結論：接種疫苗可以提高豬隻的健康抵抗力。

由於豬肉生產者和動物衛生部門面臨地方性呼吸道、生殖道、腸道和全身性疾病，以及破壞性的跨國威脅，豬疫苗的重要性日益凸顯。將疫苗接種與診斷、生物安全、監測、農場管理和獸醫主導的決策結合，才能達到最佳的疫苗接種效果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：豬疫苗市場：依疫苗類型分類

  • 去活化疫苗
    • 分裂病毒
    • 亞細胞疫苗
    • 所有病毒疫苗
  • 減毒活疫苗
    • 不同物種
    • 同種
  • mRNA
    • 未擴增的mRNA
    • 自擴增mRNA
  • 次單位疫苗
    • 多醣體次單元
    • 蛋白質次單元

第8章：豬疫苗市場：依給藥途徑分類

  • 注射
  • 鼻腔
  • 口服

第9章：豬疫苗市場：依包裝類型分類

  • 多劑量瓶
  • 預填充式注射器
  • 管瓶

第10章：豬疫苗市場：依最終用戶分類

  • 商業農場
  • 研究機構
  • 動物診所
  • 動物醫院

第11章：豬疫苗市場：依疾病類型分類

  • 經典豬瘟
  • 紅斑
  • 肺炎黴漿菌
  • 豬環狀病毒
  • 豬繁殖呼吸綜合症
  • 豬流感

第12章：豬疫苗市場：依技術分類

  • 傳統的
    • 減毒活病毒疫苗
    • 去活化全疫苗
  • DNA
  • 重組
    • 細菌表現類型
    • 昆蟲細胞表達類型
    • 酵母表現類型
  • RNA
  • VLP

第13章：豬疫苗市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章：豬疫苗市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章：豬疫苗市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Aptimmune Biologics, Inc.
  • Arko Laboratories
  • AVAC Vietnam Joint Stock Company
  • Bayer AG
  • Bimeda Holdings PLC
  • Biogenesis Bago SA
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Eli Lilly and Company
  • Endovac Animal Health
  • FATRO SpA
  • Formosa Biomedical Inc.
  • Genvax Technologies, Inc.
  • HIPRA, SA
  • Indian Immunologicals Ltd.
  • KM Biologics Co., Ltd.
  • Kyoto Biken Laboratories, Inc.
  • Malaysian Vaccines & Pharmaceuticals Sdn Bhd.
  • Medgene Labs
  • Merck & Co., Inc.
  • Nisseiken Co., Ltd.
  • PBS Animal Health
  • Phibro Animal Health Corporation
  • Virbac SA
  • Yenher Agro-Products Sdn. Bhd.
  • Zoetis Inc.
Product Code: MRR-3A2E844FD486

The Swine Vaccines Market is projected to grow by USD 3.01 billion at a CAGR of 6.30% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.96 billion
Estimated Year [2026] USD 2.08 billion
Forecast Year [2032] USD 3.01 billion
CAGR (%) 6.30%

Swine vaccines are central to modern pork production, supporting animal health, food security, antimicrobial stewardship, and continuity of international livestock trade. The sector is shaped by persistent disease pressure from economically important pathogens such as porcine reproductive and respiratory syndrome virus, porcine circovirus type 2, Mycoplasma hyopneumoniae, swine influenza virus, classical swine fever virus, and African swine fever virus. While some diseases are routinely managed through established immunization programs, others continue to drive urgent research into safer, more effective, and more scalable vaccine technologies.

Demand for swine vaccination is increasingly linked to herd-level prevention rather than reactive disease control. Producers, veterinarians, integrators, and public animal health agencies are prioritizing vaccination protocols that reduce mortality, improve reproductive performance, lower clinical disease burden, and limit secondary bacterial infections that can otherwise increase antibiotic use. Regulatory scrutiny, biosecurity standards, disease surveillance, and consumer expectations for responsibly produced pork are reinforcing the role of vaccination as a core pillar of swine health management.

The swine vaccines landscape spans live attenuated, inactivated, subunit, recombinant, vector-based, and autogenous vaccines, with innovation concentrated on broader protection, DIVA-compatible diagnostics, improved adjuvants, needle-free administration, thermostability, and rapid strain matching. As pig production systems become more intensive and globally connected, vaccine strategy is moving toward integrated disease prevention supported by diagnostics, farm data, and region-specific epidemiology.

Transformative Shifts in the Swine Vaccines Landscape

The swine vaccines landscape is undergoing transformative shifts driven by disease complexity, evolving production models, and tighter alignment between animal health and public health objectives. African swine fever has highlighted the vulnerability of pig supply chains to transboundary disease, even in regions with advanced veterinary infrastructure. Because no broadly commercialized, globally deployed African swine fever vaccine has historically been available, prevention has depended heavily on biosecurity, surveillance, movement control, and culling policies, while research has accelerated into live attenuated, gene-deleted, vectored, and subunit vaccine candidates.

Porcine reproductive and respiratory syndrome remains one of the most challenging endemic diseases for pork producers due to viral diversity, immune evasion, and herd-to-herd transmission dynamics. This has intensified interest in more precise vaccine matching, improved monitoring of circulating strains, and combined vaccination-biosecurity protocols. At the same time, long-established vaccination against PCV2 has demonstrated the value of herd-wide immunization in reducing clinical disease and improving production consistency.

The industry is also shifting from single-product decision-making toward comprehensive health programs. Vaccination choices are increasingly evaluated alongside gilt acclimatization, pig flow, all-in/all-out management, sanitation, ventilation, colostrum management, and diagnostic testing. This systems-based approach is particularly important in high-density swine regions, where pathogen circulation and co-infections can reduce vaccine performance if underlying management gaps remain unresolved.

Another major shift is the rise of precision livestock health. Digital recordkeeping, automated monitoring, and laboratory networks are enabling faster detection of disease deviations and more evidence-based vaccine scheduling. Needle-free delivery, combination vaccines, and improved administration protocols are gaining relevance as farms seek to reduce labor burden, enhance animal welfare, and improve compliance across large populations.

Cumulative Impact of Artificial Intelligence on Swine Vaccines

Artificial intelligence is beginning to reshape swine vaccine development, disease surveillance, and herd health decision-making. In vaccine research, AI-supported bioinformatics can help identify conserved antigens, evaluate immune-relevant protein structures, compare viral and bacterial genomes, and prioritize candidates for laboratory validation. This is particularly relevant for pathogens with high genetic variability, including PRRSV and swine influenza, where strain diversity complicates durable protection.

AI can also strengthen real-time disease intelligence by integrating veterinary diagnostic results, farm production records, mortality trends, feed intake, climate data, movement data, and regional outbreak notifications. When applied responsibly, these tools can help veterinarians detect abnormal patterns earlier, refine vaccination timing, and identify farms or production stages at elevated disease risk. Predictive analytics may support better allocation of diagnostic sampling and faster response to emerging variants or transboundary disease threats.

In manufacturing and quality systems, AI-enabled process analytics can support consistency by monitoring bioreactor performance, antigen yield, sterility parameters, and batch deviations. For autogenous and regionally tailored vaccines, data-driven workflows may shorten the time between pathogen identification and vaccine formulation decisions, while still requiring rigorous regulatory and safety oversight.

The cumulative impact of AI is therefore not the replacement of veterinary expertise, but the amplification of evidence-based prevention. Its value depends on data quality, interoperability, cybersecurity, transparent model validation, and alignment with animal welfare and regulatory requirements. The most meaningful adoption will occur where AI tools are embedded into veterinarian-led herd health programs and validated against field outcomes.

Key Regional Insights for Swine Vaccines

Asia-Pacific represents one of the most strategically important regions for swine vaccines because it includes several of the world's largest pork-producing and pork-consuming countries. China remains central to regional disease dynamics due to the scale of its pig population and the lasting impact of African swine fever outbreaks on production systems, biosecurity investment, and vaccine research priorities. Southeast Asian countries continue to face endemic and emerging disease pressure, including classical swine fever, PRRS, PCV2-associated disease, and African swine fever incursions, making vaccination programs closely linked with surveillance, smallholder outreach, and farm modernization. Japan, South Korea, and Australia maintain advanced veterinary regulatory systems and high biosecurity expectations, with Australia's disease-free status for several major swine pathogens shaping a prevention-first approach.

Europe has one of the most regulated animal health environments, with the European Union's Animal Health Law, surveillance systems, and farm biosecurity standards shaping vaccine deployment and disease response. African swine fever in wild boar and domestic pigs has had a major influence on regional control strategies, particularly in Eastern and Central Europe. Western European production systems emphasize vaccination as part of integrated health management, antimicrobial reduction targets, and high welfare expectations, while continued monitoring of PRRS, PCV2, Mycoplasma hyopneumoniae, swine influenza, and enteric diseases supports farm-specific vaccine protocols.

North America is characterized by highly integrated pork production, strong veterinary diagnostic capacity, and widespread adoption of vaccines against PRRS, PCV2, Mycoplasma hyopneumoniae, swine influenza, and other production-limiting pathogens. The United States and Canada emphasize coordinated surveillance, herd health planning, and rapid diagnostic confirmation, while Mexico's swine sector combines commercial integration with regional disease control priorities. Antimicrobial stewardship and supply chain continuity are key drivers of vaccine program optimization across the region.

Latin America has a diverse swine health environment, with Brazil and Mexico playing prominent roles in commercial pork production. Brazil's export-oriented pork sector places strong emphasis on disease status, veterinary controls, and preventive health programs, while regional differences in farm scale and infrastructure influence vaccination coverage across Latin America. Classical swine fever control remains relevant in parts of the region, and African swine fever preparedness has become a policy priority following re-emergence in the Caribbean.

Africa presents a complex swine vaccine landscape shaped by smallholder production, limited veterinary access in some areas, and recurring African swine fever outbreaks. The disease is endemic in parts of sub-Saharan Africa, where interactions among domestic pigs, wild suids, ticks, and informal pig movement can complicate control. Vaccination opportunities are closely tied to diagnostic access, extension services, cold chain reliability, and locally appropriate disease prevention strategies.

The Middle East has a comparatively smaller commercial swine footprint due to dietary, religious, and market factors, but animal health infrastructure remains important for biosecurity, border inspection, and disease reporting. Swine vaccine relevance is concentrated in specific production, research, and expatriate consumption contexts, while regional veterinary systems often prioritize transboundary disease preparedness across livestock species.

Key Group Insights for Swine Vaccines

NATO members are not a veterinary market bloc, but many members overlap with major swine-producing countries in North America and Europe. For these countries, animal health security intersects with national resilience, food system continuity, biosecurity, and protection against accidental or deliberate disruption of agricultural supply chains. Swine vaccine readiness is therefore part of a broader One Health and agricultural security context, particularly for preparedness against transboundary diseases such as African swine fever and classical swine fever.

G7 countries generally have mature veterinary regulatory systems, strong diagnostic capacity, and advanced research ecosystems, supporting high standards for vaccine safety, efficacy evaluation, and post-market monitoring. Within the G7, swine vaccination is closely connected to food supply resilience, responsible antibiotic use, animal welfare expectations, and preparedness for emerging or re-emerging livestock diseases.

BRICS countries collectively represent substantial influence over global swine health because China, Brazil, Russia, and India each have distinct production systems, disease challenges, and veterinary policy priorities. China's African swine fever experience has accelerated biosecurity and vaccine research, Brazil's export orientation strengthens disease prevention standards, Russia's regional disease control needs are shaped by large geography and ASF exposure, and India's growing livestock health agenda includes improving veterinary access and disease monitoring in diverse production settings.

The European Union plays an influential role in swine vaccine governance through harmonized animal health regulations, pharmacovigilance requirements, disease notification systems, and antimicrobial stewardship policies. EU member states use vaccination within broader prevention frameworks that include biosecurity, traceability, movement controls, and surveillance. African swine fever management has reinforced the need for coordinated regional response, especially where wild boar reservoirs sustain disease pressure.

ASEAN's swine vaccine priorities are shaped by dense pig populations in several member countries, mixed commercial and smallholder systems, and ongoing exposure to African swine fever, PRRS, classical swine fever, and other endemic diseases. The region's vaccination strategies increasingly depend on coordinated surveillance, farmer education, vaccine accessibility, and cross-border disease notification, particularly where informal animal movement can accelerate pathogen spread.

The GCC has limited swine production because of cultural and religious factors, yet it remains relevant to veterinary public policy through import controls, quarantine systems, laboratory readiness, and regional biosecurity planning. Swine vaccine demand is therefore highly specialized, but animal disease preparedness across the GCC benefits from investments in diagnostic infrastructure and transboundary disease monitoring.

Key Country Insights for Swine Vaccines

China remains one of the most consequential countries for swine vaccines due to the scale of its pig industry and the profound restructuring that followed African swine fever outbreaks. Large-scale farms have expanded biosecurity and veterinary protocols, while disease control continues to focus on ASF preparedness, PRRS, PCV2, classical swine fever, and other endemic pathogens. The United States has a large, highly integrated pork sector where vaccination programs are central to controlling PRRS, PCV2, Mycoplasma hyopneumoniae, swine influenza, erysipelas, and other production diseases. Strong diagnostic networks, veterinarian-led health planning, and biosecurity protocols guide vaccine selection and timing. Japan has high biosecurity standards and a sophisticated veterinary framework, with vaccination decisions shaped by disease status, regulatory controls, and food safety expectations. India's swine sector is smaller than its broader livestock economy but important in specific regions, particularly in the northeast, where vaccination, veterinary access, and disease awareness are critical for smallholder resilience.

Germany, France, Italy, and Spain are major European pork producers where vaccination is embedded in integrated health management, antimicrobial reduction efforts, and compliance with European regulatory standards. Germany emphasizes biosecurity, welfare, and surveillance, while France combines structured veterinary oversight with disease prevention across diverse production models. Spain's intensive pork production system makes disease prevention, PRRS control, and coordinated veterinary oversight especially important. Italy's diversified production, including specialty pork supply chains, places value on herd stability, traceability, and disease prevention. The United Kingdom maintains rigorous disease surveillance and biosecurity protocols, with swine vaccines used in targeted health programs that reflect farm-specific disease history and veterinary guidance.

Australia maintains strict biosecurity and border controls to protect its animal health status, using vaccination where appropriate while prioritizing exclusion of major exotic swine diseases. South Korea combines modern commercial production with strong government-led disease control measures, shaped by experiences with African swine fever and other livestock disease threats. Canada emphasizes herd health planning, traceability, and disease prevention, with export-oriented production reinforcing strict veterinary standards. Russia faces significant regional swine disease challenges, including African swine fever exposure, making surveillance, biosecurity, and vaccine research priorities for domestic pork resilience.

Brazil is a leading pork producer with strong export ambitions, so preventive vaccination, disease monitoring, and maintenance of recognized animal health status are strategically important. The country's commercial sector uses structured herd health programs, while regional differences require adaptable veterinary outreach. Mexico combines major commercial pork operations with regionally varied production systems, making vaccine access, disease surveillance, and biosecurity important across different farm scales.

Actionable Recommendations for Swine Vaccine Leaders

Industry leaders should prioritize integrated swine health programs that combine vaccination, diagnostics, biosecurity, nutrition, welfare, and farm management rather than relying on vaccines as standalone interventions. Vaccine protocols should be built from farm-specific disease history, laboratory confirmation, pathogen sequencing where relevant, production stage risk, maternal antibody status, and veterinarian-supervised outcome monitoring.

Manufacturers and research teams should invest in vaccine platforms that address antigenic diversity, rapid strain adaptation, DIVA compatibility, improved safety profiles, and practical administration in large herds. African swine fever, PRRS, and swine influenza require continued scientific focus because of their economic consequences, genetic variability, and implications for trade and food security.

Producers should strengthen cold chain handling, staff training, accurate dosing, booster compliance, and post-vaccination monitoring to protect vaccine effectiveness. Digital herd records should be used to connect vaccination events with mortality, morbidity, reproductive performance, medication use, and diagnostic results. This creates a feedback loop for evidence-based protocol refinement.

Policy stakeholders should support transparent disease reporting, regional laboratory capacity, responsible vaccine authorization, and farmer education programs, especially in areas with smallholder production and limited veterinary access. Cross-border collaboration is essential for transboundary diseases, as pathogen movement rarely follows administrative boundaries.

Across the value chain, leaders should align swine vaccination strategies with antimicrobial stewardship and One Health objectives. Demonstrating reductions in clinical disease, secondary infections, and antibiotic dependence can strengthen stakeholder confidence and support sustainable pork production.

Research Methodology for Swine Vaccines Analysis

This executive summary is developed using a structured secondary research approach focused on verified animal health, veterinary epidemiology, and regulatory information. Core inputs include publicly available materials from national veterinary authorities, intergovernmental animal health organizations, peer-reviewed scientific literature, disease notification systems, livestock health guidelines, and recognized veterinary public health sources.

The methodology emphasizes triangulation across multiple credible references to validate disease relevance, regional patterns, vaccine use context, and technology trends. Insights are assessed for consistency with established swine health knowledge, including pathogen epidemiology, production system characteristics, biosecurity practices, and regulatory frameworks. Particular attention is given to avoiding unsupported claims, speculative commercial projections, and unverified performance assertions.

Qualitative analysis is used to interpret how disease burden, farming structure, veterinary infrastructure, regulatory policy, and biosecurity maturity influence swine vaccine adoption. Regional, group, and country-level insights are synthesized into narrative form to support search visibility while maintaining evidence-based accuracy. The analysis excludes market sizing, market share, and forecasting, focusing instead on strategic, operational, scientific, and policy-relevant developments.

Conclusion: Advancing Resilient Swine Health Through Vaccination

Swine vaccines are becoming increasingly important as pork producers and animal health authorities confront endemic respiratory, reproductive, enteric, and systemic diseases alongside high-impact transboundary threats. The strongest vaccination outcomes occur when immunization is integrated with diagnostics, biosecurity, surveillance, farm management, and veterinarian-led decision-making.

The landscape is shifting toward precision prevention, supported by improved vaccine platforms, farm data, sequencing, digital monitoring, and AI-assisted analytics. However, successful implementation will depend on field validation, regulatory oversight, cold chain reliability, producer training, and regionally appropriate disease control strategies.

Across Asia-Pacific, Europe, North America, Latin America, Africa, and the Middle East, swine vaccine priorities differ by production scale, disease status, veterinary infrastructure, and policy environment. Yet the strategic direction is consistent: healthier herds, reduced disease losses, improved antimicrobial stewardship, and stronger resilience of pork supply chains. Stakeholders that align vaccine innovation with practical farm execution and transparent disease intelligence will be best positioned to advance sustainable swine health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Swine Vaccines Market, by Vaccine Type

  • 7.1. Introduction
  • 7.2. Inactivated Vaccine
    • 7.2.1. Split Virus
    • 7.2.2. Subcellular
    • 7.2.3. Whole Virus
  • 7.3. Live Attenuated Vaccine
    • 7.3.1. Heterologous
    • 7.3.2. Homologous
  • 7.4. MRNA
    • 7.4.1. Non Amplifying MRNA
    • 7.4.2. Self Amplifying MRNA
  • 7.5. Subunit Vaccine
    • 7.5.1. Polysaccharide Subunit
    • 7.5.2. Protein Subunit

8. Swine Vaccines Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Injection
  • 8.3. Nasal
  • 8.4. Oral

9. Swine Vaccines Market, by Packaging Type

  • 9.1. Introduction
  • 9.2. Multi Dose Bottle
  • 9.3. Pre Filled Syringe
  • 9.4. Vial

10. Swine Vaccines Market, by End User

  • 10.1. Introduction
  • 10.2. Commercial Farms
  • 10.3. Research Institutes
  • 10.4. Veterinary Clinics
  • 10.5. Veterinary Hospitals

11. Swine Vaccines Market, by Disease Type

  • 11.1. Introduction
  • 11.2. Classical Swine Fever
  • 11.3. Erysipelas
  • 11.4. Mycoplasma Pneumonia
  • 11.5. Porcine Circovirus
  • 11.6. Porcine Reproductive And Respiratory Syndrome
  • 11.7. Swine Influenza

12. Swine Vaccines Market, by Technology

  • 12.1. Introduction
  • 12.2. Conventional
    • 12.2.1. Attenuated Live
    • 12.2.2. Killed Whole
  • 12.3. DNA
  • 12.4. Recombinant
    • 12.4.1. Bacteria Expressed
    • 12.4.2. Insect Cell Expressed
    • 12.4.3. Yeast Expressed
  • 12.5. RNA
  • 12.6. VLP

13. Swine Vaccines Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Swine Vaccines Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. Swine Vaccines Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Aptimmune Biologics, Inc.
  • 17.2. Arko Laboratories
  • 17.3. AVAC Vietnam Joint Stock Company
  • 17.4. Bayer AG
  • 17.5. Bimeda Holdings PLC
  • 17.6. Biogenesis Bago S.A.
  • 17.7. Boehringer Ingelheim International GmbH
  • 17.8. Ceva Sante Animale
  • 17.9. Eli Lilly and Company
  • 17.10. Endovac Animal Health
  • 17.11. FATRO S.p.A.
  • 17.12. Formosa Biomedical Inc.
  • 17.13. Genvax Technologies, Inc.
  • 17.14. HIPRA, S.A.
  • 17.15. Indian Immunologicals Ltd.
  • 17.16. KM Biologics Co., Ltd.
  • 17.17. Kyoto Biken Laboratories, Inc.
  • 17.18. Malaysian Vaccines & Pharmaceuticals Sdn Bhd.
  • 17.19. Medgene Labs
  • 17.20. Merck & Co., Inc.
  • 17.21. Nisseiken Co., Ltd.
  • 17.22. PBS Animal Health
  • 17.23. Phibro Animal Health Corporation
  • 17.24. Virbac SA
  • 17.25. Yenher Agro-Products Sdn. Bhd.
  • 17.26. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SWINE VACCINES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL SWINE VACCINES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL SWINE VACCINES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL SWINE VACCINES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SWINE VACCINES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL SWINE VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL SWINE VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL SWINE VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL SWINE VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL SWINE VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL SWINE VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL SWINE VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL SWINE VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL SWINE VACCINES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL SWINE VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INACTIVATED VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INACTIVATED VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INACTIVATED VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SPLIT VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SPLIT VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SPLIT VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SUBCELLULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SUBCELLULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SUBCELLULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL WHOLE VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL WHOLE VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL WHOLE VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LIVE ATTENUATED VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVE ATTENUATED VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LIVE ATTENUATED VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HETEROLOGOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HETEROLOGOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HETEROLOGOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HOMOLOGOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HOMOLOGOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HOMOLOGOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NON AMPLIFYING MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON AMPLIFYING MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NON AMPLIFYING MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SELF AMPLIFYING MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SELF AMPLIFYING MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SELF AMPLIFYING MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SUBUNIT VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SUBUNIT VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SUBUNIT VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POLYSACCHARIDE SUBUNIT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POLYSACCHARIDE SUBUNIT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POLYSACCHARIDE SUBUNIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MULTI DOSE BOTTLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MULTI DOSE BOTTLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MULTI DOSE BOTTLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PRE FILLED SYRINGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PRE FILLED SYRINGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PRE FILLED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMMERCIAL FARMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMMERCIAL FARMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COMMERCIAL FARMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CLASSICAL SWINE FEVER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CLASSICAL SWINE FEVER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CLASSICAL SWINE FEVER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ERYSIPELAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ERYSIPELAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ERYSIPELAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MYCOPLASMA PNEUMONIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MYCOPLASMA PNEUMONIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MYCOPLASMA PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PORCINE CIRCOVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PORCINE CIRCOVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PORCINE CIRCOVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SWINE INFLUENZA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SWINE INFLUENZA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SWINE INFLUENZA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CONVENTIONAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CONVENTIONAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CONVENTIONAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ATTENUATED LIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ATTENUATED LIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ATTENUATED LIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL KILLED WHOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL KILLED WHOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL KILLED WHOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL RECOMBINANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RECOMBINANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RECOMBINANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BACTERIA EXPRESSED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BACTERIA EXPRESSED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BACTERIA EXPRESSED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INSECT CELL EXPRESSED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INSECT CELL EXPRESSED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INSECT CELL EXPRESSED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL YEAST EXPRESSED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL YEAST EXPRESSED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL YEAST EXPRESSED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL RNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL RNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL RNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL VLP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL VLP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VLP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL SWINE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE SWINE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE SWINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE SWINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE SWINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA SWINE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA SWINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA SWINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA SWINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL SWINE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. NATO SWINE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. NATO SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. NATO SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 209. NATO SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 210. NATO SWINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 211. NATO SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. NATO SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. NATO SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO SWINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 218. NATO SWINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 219. G7 SWINE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. G7 SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. G7 SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 222. G7 SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 223. G7 SWINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 224. G7 SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. G7 SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. G7 SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. G7 SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. G7 SWINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 231. G7 SWINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS SWINE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS SWINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS SWINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS SWINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN SWINE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN SWINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN SWINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN SWINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 271. GCC SWINE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 272. GCC SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. GCC SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 274. GCC SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 275. GCC SWINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 276. GCC SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, 2018-2032 (USD MILLION)
  • TABLE 277. GCC SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 278. GCC SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. GCC SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. GCC SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. GCC SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. GCC SWINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 283. GCC SWINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 284. GLOBAL SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA SWINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA SWINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA SWINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES SWINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES SWINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES SWINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 311. JAPAN SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. JAPAN SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. JAPAN SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 314. JAPAN SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 315. JAPAN SWINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 316. JAPAN SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, 2018-2032 (USD MILLION)
  • TABLE 317. JAPAN SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 318. JAPAN SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. JAPAN SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 320. JAPAN SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. JAPAN SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 322. JAPAN SWINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 323. JAPAN SWINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 324. INDIA SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 325. INDIA SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. INDIA SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 327. INDIA SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 328. INDIA SWINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 329. INDIA SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, 2018-2032 (USD MILLION)
  • TABLE 330. INDIA SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 331. INDIA SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. INDIA SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 333. INDIA SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. INDIA SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 335. INDIA SWINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 336. INDIA SWINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 337. GERMANY SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 338. GERMANY SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 339. GERMANY SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 340. GERMANY SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 341. GERMANY SWINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 342. GERMANY SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, 2018-2032 (USD MILLION)
  • TABLE 343. GERMANY SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 344. GERMANY SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. GERMANY SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 346. GERMANY SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 347. GERMANY SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 348. GERMANY SWINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 349. GERMANY SWINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 350. UNITED KINGDOM SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 351. UNITED KINGDOM SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 352. UNITED KINGDOM SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 353. UNITED KINGDOM SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 354. UNITED KINGDOM SWINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 355. UNITED KINGDOM SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, 2018-2032 (USD MILLION)
  • TABLE 356. UNITED KINGDOM SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 357. UNITED KINGDOM SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 358. UNITED KINGDOM SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 359. UNITED KINGDOM SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 360. UNITED KINGDOM SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 361. UNITED KINGDOM SWINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 362. UNITED KINGDOM SWINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 363. AUSTRALIA SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 364. AUSTRALIA SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 365. AUSTRALIA SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 366. AUSTRALIA SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 367. AUSTRALIA SWINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 368. AUSTRALIA SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, 2018-2032 (USD MILLION)
  • TABLE 369. AUSTRALIA SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 370. AUSTRALIA SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 371. AUSTRALIA SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 372. AUSTRALIA SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 373. AUSTRALIA SWINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 374. AUSTRALIA SWINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 375. AUSTRALIA SWINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 376. FRANCE SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 377. FRANCE SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 378. FRANCE SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 379. FRANCE SWINE VACCINES MARKE